Phase II study to evaluate the efficacy and safety of mirogabalin for CIPN in patients with gastrointestinal cancer.
收藏NIAID Data Ecosystem2026-03-14 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/103511
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: Initial dose of mirogabalin orally twice daily, then titrated at intervals of at least 1 week to a maintenance dose orally twice daily.
Primary outcome(s): Change in 24-hour pain (including numbness) average NRS (Numeric Rating Scale) from the start of mirogabalin administration to 6 weeks.
Study Design: Single arm Non-randomized
创建时间：
2022-12-15
